Article Information
- Received May 10, 2021
- Revision received August 27, 2021
- Accepted August 30, 2021
- First published September 16, 2021.
- Version of record published October 20, 2021.
Author Information
Author contributions
Author contributions: J.Z., J.N.A., T.M.H., and W.J.J. designed research; J.Z. and S.L.B. performed research; J.Z. analyzed data; J.Z. wrote the first draft of the paper; J.Z., J.N.A., T.M.H., S.L.B., and W.J.J. edited the paper; J.Z. and W.J.J. wrote the paper.
Disclosures
- Received May 10, 2021.
- Revision received August 27, 2021.
- Accepted August 30, 2021.
This work was supported by National Institutes of Health Grants T32-NS095939 (to J.Z.), F31-AG062090 (to J.N.A.), F32-AG057107 (to T.M.H.), R01-AG062542 (to W.J.J.), and R01-AG034570 (to W.J.J.) and by the Rainwater Charitable Foundation (W.J.J.). Avid Radiopharmaceuticals enabled the use and the 18F-Flortaucipir tracer but did not provide direct funding and were not involved in data analysis or interpretation. We thank R. La Joie for assisting with selecting regions of interest and visualization of results.
W.J.J. consults for Genentech, Biogen, and Bioclinica. All other authors declare no competing financial interests.
- Correspondence should be addressed to Jacob Ziontz at jacob_ziontz{at}berkeley.edu
Funding
HHS | National Institutes of Health (NIH)
T32-NS095939; F31-AG062090; F32-AG057107; R01-AG034570Rainwater Charitable Foundation
Other Version
- previous version (September 16, 2021).
- You are viewing the most recent version of this article.
